Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers
Datamonitor, December 2010
The "Pipeline Insight: Cancer Overview – Breast and Gynecological Cancers" report is due to be published in December 2010.
This report will cover the following key topics:
- Pipeline Overview and Dynamics
- Epidemiology
- Market overview
- R&D Approach
- Pipeline Analysis & Forecasts: Breast
- Pipeline Analysis & Forecasts: Ovarian
- Pipeline Analysis & Forecasts: Cervical
- Innovative Early-Stage Approaches
This report pack includes the Full report (pdf), Datapack (xls) and Executive presentation (ppt)
Provisional Table of Contents
Overview
Catalyst
Summary
Executive Summary
Strategic scoping and focus
Insight into the disease market
Related reports
Upcoming related reports
1. Pipeline Overview and Dynamics
Key findings
Pipeline overview
Comparative forecasts
Datamonitor pipeline assessment summary
Key companies involved in the disease
Key R&D company strategies
2. Epidemiology
Key findings
Definition
Patient segmentation
Epidemiology
Seven major markets
Rest of the world
3. Market overview
Key findings
Current treatment options
Current gold standard and comparator therapies
Gold standard or comparator therapy
Current market overview
Unmet need in disease
Target product profile versus current level of attainment
4. R&D Approach
Key findings
Clinical trial design in disease
5. Pipeline Analysis & Forecasts: Breast
Key findings
Overview for Breast
Pipeline summary
Comparative forecasts
Afatinib (BIBW 2992; Boehringer Ingelheim)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Afinitor (everolimus; Novartis)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Iniparib (BSI-201; BiPar Sciences/Sanofi-Aventis)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Eribulin (E7389; Eisai)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Pertuzumab (Genentech/Roche/Chugai)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Ramucirumab (IMC-1121B; Eli Lilly)
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
Trastuzumab-DM1 (ImmunoGen/Genentech/Roche/Chugai)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical and commercial attractiveness
Datamonitor drug assessment summary for trastuzumab-DM1
Forecasts to 2019
Votrient (pazopanib; GlaxoSmithKline)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical and commercial attractiveness
Datamonitor drug assessment summary for trastuzumab-DM1
Forecasts to 2019
6. Pipeline Analysis & Forecasts: Ovarian
Key findings
Overview for Breast
Pipeline summary
Comparative forecasts
Abagovomab (ACA-125; Menarini/CellControl BioMedical)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical and commercial attractiveness
Datamonitor drug assessment summary for trastuzumab-DM1
Forecasts to 2019
Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
Avastin (bevacizumab; Genentech/Roche/Chugai)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
Farletuzumab (MORAb-003; Morphotek/Eisai)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
Tarceva (erlotinib; Genentech/Roche/Chugai/OSI)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
Votrient (pazopanib; GlaxoSmithKline)
Drug overview
Drug profile
Key historical events
SWOT analysis
Clinical trial data
Clinical attractiveness
Commercial attractiveness
Datamonitor drug assessment summary
Forecasts to 2019
7. Pipeline Analysis & Forecasts: Cervical
Key findings
Overview for Breast
Pipeline summary
Comparative forecasts
ISA-HPV-01
Drug overview
Drug profile
Key historical events
Clinical trial data
SWOT analysis
Datamonitor drug assessment summary for afatinib
Clinical and commercial attractiveness
Forecasts to 2019
8. Innovative Early-Stage Approaches
Key findings
Innovative therapeutic approach
Innovative therapeutic approach
Innovative therapeutic approach
The future of treatment in disease
Bibliography
For each chapter
Journal papers
Websites
Other
APPENDIX
Methodology
Forecast methodology
Epidemiology forecasts
Product forecasts
Definition of a standard unit (only use if ForeSight model used to forecast)
Derivation of sales forecasts and pricing trends
Exchange rates
Drug assessment scorecard
Contributing experts
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
